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CHAPTER 1 GENERAL BACKGROUND
Human Cytomegalovirus
Epidemiology. Human cytomegalovirus (HCMV) is one of the many members of the
Herpesviridae. It is a worldwide opportunistic pathogen typically acquired early in life. It is
estimated that 40-100% of the population have HCMV antibody present in their blood.
Seroprevalence increases with age and approximately 85% of adults over the age of 70 is HCMV
seropositive (1).

Other factors associated with increased seroprevalence include ethnicity,

socioeconomic status, and living in crowded conditions. Primary infections are asymptomatic in
majority of cases.

However, immunocompromised patients are at higher risk for serious

manifestations as well as recurrence. Illness may manifest as an influenza-like illness to severe
disease with multi-system organ failure or dysfunction. The protracted effects alone of HCMV
disease on these high-risk populations warrants a development of improve treatment and
prevention of this viral infection.
HCMV is transmitted from person to person through a variety of ways which include
contact with infected body fluids including saliva, tears, breast milk, urine, and genital
secretions. Seroconversion has been documented between family members and individuals in
day care centers where unhygienic habits of children make it easy to transmit the virus;
prolonged viral shedding is common in children (2). Sexual activity plays a role in acquiring
HCMV infection. Since the virus is present in genital secretions, having multiple sexual partners
or a history of high-risk sexual activity increases the likelihood of infection. The virus can also
be excreted asymptomatically, thus, frequent shedding in saliva and urogenital secretions enable
asymptomatic transmission of the virus (2).
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HCMV is one of the TORCH microbes: a group of microbes that can cross the placenta
(Toxoplasma gondii, (Other), rubella, HCMV, herpes simplex virus 1 and 2). Fetuses have a high
risk of acquiring HCMV disease in utero during primary maternal infection. Also, it can be
acquired perinatally from exposure to birth canal secretions during delivery, or postnatally from
maternal milk during breast feeding.
In addition, HCMV can also be transmitted via blood products and tissue and organ
transplants.
Like all members of the Herpesviridae, HCMV exhibits latency that can reactivate
periodically especially when the host becomes immunosuppressed. HCMV establishes latency
in the progenitors of the myeloid lineage, mainly the monocyte precursors (3).

HCMV

replication occurs widely in multiple tissues, including neutrophils, leukocytes, and monocytes,
which can serve as vehicles for spread (4). Due to its broad tissue tropism, it can cause a wide
spectrum of disease.
Clinical disease.

Most adults possess HCMV antibodies and are normally

asymptomatic. A self-limiting febrile illness is a common presentation during primary infection.
Symptomatic infection may present as mononucleosis (also known as heterophile antibody
negative mononucleosis to distinguish from that caused by Epstein-Barr virus.) Mononucleosis
characterized by fever, chills, sweats, headache and pharyngitis is more commonly observed in
young adults. Skin rashes such as macular, papular, or rubelliform spots may accompany these
signs and symptoms (3).

Common lab anomalies will be atypical lymphocytes,

thrombocytopenia, elevated rheumatoid factor and anemia.

In some cases, elevated atypical
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lymphocytes and liver enzymes could persist for many months. A post-viral fatigue syndrome
can occur in some adults (5).
For the immunocompromised host, the primary HCMV infection replicates
uncontrollably and can lead to disseminated infections.

HCMV infection in

immunocompromised hosts can have different clinical manifestations depending on the
population. Seropositive bone marrow transplant patients, or those receiving a positive donor
bone marrow, have a high risk of developing severe HCMV pneumonitis that can lead to death.
The presentation of pneumonitis is presumed to be a pathological consequence from the host
immune response against the virus (3). AIDS patients commonly develop viremia, progressive
retinitis that may lead to blindness, and diarrhea from HCMV colitis.

Further, HCMV can

disseminate to the brain causing encephalitis (3).
HCMV colitis is uncommon in immunocompetent people.

However in the

immunocompromised host, it can lead to fulminating colitis manifesting as severe bloody
diarrhea, abdominal pain, and fevers. Diagnosis requires a high degree of clinical suspicion and
a biopsy is generally needed in almost all cases (6).
Other clinical syndromes described with HCMV is pericarditis and myocarditis. Post
HCMV Guillain-Barré syndrome is a well described but uncommon sequela following resolution
of infection (5).
Congenital HCMV. HCMV is the most common cause of congenital infections, about
1% of live births, and approximately 10 percent of those are symptomatic at birth (7). If due to
primary maternal infection, the fetus is more likely to be symptomatic at birth or experience
long-term sequelae which can include progressive hearing loss, visual and intellectual
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impairment, severe disease including organ damage, CNS abnormalities, or death.

Disease

manifestation is most severe if primary infection was acquired during the first trimester of fetal
development. Sensorineural hearing loss (SNHL) is the most common sequelae of congenital
disease caused by viral spread into the inner ear structures forming a focus of infection
accompanied by inflammation. Other signs and symptoms include thrombocytopenia purpura,
hepatitis, pneumonitis and myocarditis (3).
HCMV infection in the elderly. In immunocompetent adults, illness is generally self
limiting. It is one of the viral illness which can present as fever of unknown origin lasting for
more than 4-6 weeks with absence of lab anomalies. In such cases, diagnosis is difficult and
other infections, malignancies and cancers have to be ruled out (8).
Lab Diagnosis.

HCMV can be detected in a variety of specimens: tissue, urine,

respiratory secretions, CSF, peripheral blood, and other body fluids. However, since most of us
can shed this virus asymptomatically, diagnosis of symptomatic infection is best confirmed by
detection of HCMV DNA from sterile body fluids (e.g., peripheral blood and its components,
CSF.) PCR method is the gold standard for testing owing to its high sensitivity and faster turn
around time compared to cell cultures. False positive can occur and interpretation of PCR results
should correlate with clinical symptoms, and in some cases, an H&E tissue biopsy confirmation
may be necessary (9).
Other methods available include detection of IgG or IgM antibodies by serology (e.g.,
ELISA), detection of HCMV pp65 antigen in leukocytes, growth in human fibroblast cell
cultures, and histopathology. In histopathology slides, HCMV exhibits a characteristic “Owl’s
eye” intranuclear inclusions in a cytomegalic infected cell (Fig. 1), although this feature may be
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absent in some infected organs. Biopsies may be performed if organ involvement is suspected,
or in cases of disseminated infections.
Diagnosis of congenital HCMV can be done in utero by amniocentesis if the infection is
suspected due to primary maternal infection or from abnormal findings on the ultrasound. The
sensitivity of this sample depends on the timing of collection: there is higher sensitivity if
collected after 21 weeks of gestation and a 6 weeks lag time between maternal infection and
collection that takes into account replication of the virus in the placenta, transmission to the fetus
and consequent replication in the fetal kidney and excretion into the amniotic fluid (10). The
amniotic fluid is then tested for the presence of HCMV DNA using PCR.
For perinatal diagnosis, the standard method is a PCR test on saliva collected within 3
weeks of birth. This is followed by a urine test for confirmation. The saliva must be collected
at least 1 hour after breast feeding because HCMV-positive mothers can shed HCMV in their
breast milk and may cause a false positive result on the saliva sample collected soon after breast
feeding (10).
Molecular. HCMV is a betaherpesvirus with an enveloped virion that houses a linear
double-stranded DNA. At approximately 230 kbp, it is the largest genome among the human
herpesviruses. Primary attachment for entry requires the viral glycoproteins gB, gH, and gL that
attach to the heparan sulfate proteoglycan receptors on the host cells. The virus may either enter
a lytic cycle, or go latent.

The lytic replication cycle has three phases beginning with the

expression of the immediate early genes that code for regulatory proteins, early genes that code
for proteins used for replication, and the late genes that regulate the structural proteins to make
complete virions. The permissiveness of a cell for the lytic cycle or the pathogenesis of an
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HCMV infection involves complex interactions between the virus and its host. The large HCMV
genome encodes genes that allow the virus to counteract many host defenses.
Treatment and Prevention.

Cell-mediated immunity is the primary immune response

required to control HCMV infection, which explains why the high-risk groups for severe disease
are those who have deficiencies in CD4+ and CD8+ lymphocytes. Common antiviral drugs used
against HCMV (i.e., foscarnet, valganciclovir, ganciclovir) are highly toxic and are only used to
treat high risk groups such as those with congenital disease and infections in
immunocompromised hosts.

No vaccines are currently available.

Preventative measures to

curtail the risk of transmission include good hand washing/proper hygienic practices, and using
seronegative donor blood or tissue products (11).

A deeper understanding of the effects of

HCMV and the mechanism of its pathogenicity on infected cells is vital to the development of
vaccines and new antiviral drugs that are less toxic.
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FIG 1 Pancreas H&E stain showing Owl’s eye morphology (arrow) of an infected cell. 40X
cropped. Tissue slide from Detroit Children’s Hospital.
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CHAPTER 2 DETECTING THE cVAC STRUCTURE IN VIVO
Introduction
HCMV induces cytopathic effects in host cells typically characterized by an enlarged
kidney-bean shaped nucleus bent around a Golgi ring with the endosomes at the center forming
the structure known as the cytoplasmic virion assembly complex (cVAC) (Fig. 2). The cVAC is
where virus particles are assembled and trafficked out of the cell.

This structure has been

elucidated and demonstrated in vitro in multiple studies (12-14), however, no in vivo studies
have been done. Cellular markers that detect the cVAC structure include the Golgi, trans-Golgi,
and early endosomes. We aim to detect by immunofluorescence assay some of the cellular and
viral components that form the cVAC to learn if the formation of this complex can be observed in
vivo.
Materials and Methods
Materials. 12 sets of formalin-fixed, paraffin-embedded tissue slides from children with
congenital HCMV were obtained from Detroit Children’s Hospital courtesy of Dr. Janet Poulik,
M.D., Department of Pathology, Detroit Medical Center, with Institutional Review Board (IRB)
approval. Dr. Noman Hussain (Fellow in Infectious Diseases) was instrumental in getting the
approval from the IRB and helped during the process of developing the experimental methods.
The tissue slides were taken from various infected anatomical sites: lung, colon, stomach,
intestines, trachea, etc., and the quantity of infected cells in each set were assessed using a
Hematoxylin & Eosin (H&E) stained slide. Slides that exhibit more than 2 infected cells per
40X field were used for the experiment. In addition to the slides from congenitally infected
children, commercially prepared placenta (Azer Scientific) and lung (StatLab) tissue slides were
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also used in the early phase of the experiment. Commercially prepared CMV infected control
slides (Bion, Inc) were used to verify the functionality of the antibodies in each experiment (Fig.
3)
Deparaffinization, rehydration, and antigen retrieval.

Based on preliminary

experiments, the optimized protocol described in this section was used.
Paraffin used to solidify the tissue sections for slicing must be removed first prior to
staining to allow buffers and antibodies to penetrate. This was done by baking the slides at 50℃
for 1 hour to melt the paraffin wax followed by three xylene washes at 5 minutes each. Next,
xylene was removed with two 100% ethanol washes, then the tissue slides were hydrated
gradually through 95% and 70% alcohol washes and two washes with distilled water.

The

formalin fixative used to preserve the integrity of the tissue sections induces the formation of
methylene bridges between proteins that may potentially block antigenic sites. Heating the slides
can cleave these cross-links between proteins (15). This was accomplished with a heat-induced
antigen retrieval (HIER) method by immersing the slides in a buffer jar inside an 80-90 ℃ water
bath.

As the heating and subsequent cooling process cause folding and re-folding of the

polypeptides, masked epitopes are exposed. The re-folding of the polypeptide chains can be
affected by the buffer pH which determines how the positive- and negatively-charged
polypeptides react with each other (15).

We made our own buffers using Abcam’s

recommendations (16). In addition, we used R-Universal Epitope Recovery Buffer (Electron
Microscopy Sciences). As shown in Tables 1 and 2, we tried different duration and temperature
of baking and antigen retrieval, and explored different buffers to optimize the deparaffinization,
rehydration, and antigen-retrieval steps for our tissue slides.
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Immunofluorescent staining. After the HIER step, the slides were washed with PBS
and autofluorescence was quenched by incubation in 50 mM ammonium chloride for 30 minutes.
This was followed by permeabilization in blocking serum with 0.2% Triton-X for 25 minutes,
incubation in blocking serum only for 1 hour, then stained with primary antibodies overnight at
4℃ (antibodies described in Table 3). The slides were then stained with fluorescent-tagged
secondary antibodies for 1 hour at room temperature (Alexa Fluor 488-conjugated goat antimouse IgG and Alexa Fluor 568-conjugated goat anti-rabbit IgG, both from Molecular Probes,
Carlsbad, CA). The slides were mounted with Vectashield containing DAPI (4’, 6-diamidino-2phenylindole) (Vector Laboratories Inc., CA). Imaging was done on a Nikon E800 fluorescence
microscope.

As shown in Table 2, variations in the duration of incubation were performed to

specifically optimize the staining procedure for our slides.
Results
The ability to visualize cellular structures varied with the quality of the slides and the
staining process performed. Initial efforts included identification of the optimal procedure to
clear the paraffin from the different types of tissue slides, detecting the epitopes of interest, and
quenching the autofluorescence typically observed in tissue sections. Once we developed the
optimum experimental procedure by trying different combinations of the factors shown in Tables
1 and 2, (optimal protocol is as described in the Deparaffinization…, and Immunofluorescent
staining sections above), we were able to detect good nuclear IE2 staining in most of the slides
(Figs. 4 and 5). Other viral proteins tested such as glycoprotein B (gB) and pp28 were also
detected (Figs. 5A, 5B) which proved the ability of the procedure to detect HCMV infected cells.
As expected, the tissue sections with more infected cells per field (i.e., colon, ovary, pancreas)
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provided better results.

Fig. 6 shows a classic kidney-bean shaped infected colon cell with

staining of the Golgi and early endosomes evident in the area of the cVAC.
Staining of the Golgi and early endosomes, structures classically associated with the
cVAC, were not consistently evident in every slide tested. This could be attributed to the threedimensional nature of the tissue sections which affects the orientation of the infected cell seen
microscopically; an example is shown on Fig. 7 (12).
Discussion
The objective of this work was to detect the cVAC structure in FFPE tissue slides. By
developing an optimized staining procedure, we discovered that the cVAC is formed in tissue
specimens.
An important aspect to keep in mind when working with tissue slides as opposed to a
monolayer of cells grown in culture is the three dimensional aspect of the specimen. As the
FFPE section is sliced, the structures of interest could be severed and exhibit a shape or form that
is not consistent with their typical morphology. Also, the angle of the cell on the tissue could
hide expected features. Fig. 6 from our experiment suggests that the cVAC is indeed present in
tissue as it is in cell cultures. More robust evidence is needed however, and would require a
more extensive and three-dimensional microscopic study of ideally-positioned infected cells in
tissue sections. A limitation of this study was the amount of acceptable slides available for
testing. A majority of the slides contained rare to very few scattered infected cells and were not
ideal for testing. Interesting to note, this “scattered infection” seems to be a feature consistent
with how HCMV establishes an infection. Mayer et al. recently reported that HCMV spreads to
neighboring cells inefficiently and normally requires numerous tries to establish an infection
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(17). This phenomenon can be observed on Fig. 1 which shows 2 infected cells in the center
surrounded by many uninfected cells.
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Uninfected HLF
DAPI (Nucleus)
GM130 (Golgi)
EEA1 (Early/recycling endosomes)

HCMV in HLF cells 5 dpi

FIG 2 HCMV induces cytopathic effects in host cells forming the cVAC. Das and Pellett, J. Virol. 2011.

FIG 2 HCMV induces cytopathic effects in host cells forming the cVAC. (Left) Uninfected
HLF cell (human lung fibroblast) with the Golgi adjacent to the nuclei and the early endosomes
scattered around the cell. (Right) Infected cell 5 dpi (days post infection) showing an enlarged
bent nucleus with the Golgi forming a ring structure and the endosomes localized in the center.
Das and Pellett, J. Virol. 2011.
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A

Negative

B

Positive

DAPI (Nucleus)
IE2 (Nucleus), GM130 (Golgi)
EEA1 (Early/recycling endosomes)
FIG 3 Control slides showing staining of the corresponding antibodies. (A) Negative control

FIG 3 Commercial
fibroblast
slides that show staining of the corresponding antibodies.
well. (B) Positive
controlcontrol
well.
(A) Negative control with cells staining for the cellular markers GM130 and EEA1. (B)
Positive control showing the classic large kidney-bean shaped nucleus on top right staining
with the viral nuclear marker IE2, and the cellular Golgi and EEA1 markers localized in the
center, as expected.

EDTA pH 8.0

1 hour in room temperature; antibody diluted in

Primary antibody incubation period

Heat-induced antigen retrieval water bath temperature

0 minutes
15 minutes
30 minutes

60 ℃
85-90 ℃

Heat-induced antigen retrieval incubation period

Blocking step duration with 50 mM ammonium chloride

0 minutes
20 minutes
30 minutes
1 hour

Abcam recipe:
1.21 g of Tris and 0.37 g of EDTA
dissolved in 1 L of deionized water. pH
adjusted to 9.0 with NaOH. 0.5 ml
Tween 20 added.

0 minutes
15 minutes
25 minutes

not performed
50-55 ℃ for 1 hour

Bake slides

R-Universal

10 mM Tris base, 1 mM EDTA solution, R-Universal Epitope Recovery Buffer
0.05% Tween 20, pH 9.0
(Electron Microscopy Sciences)

Tris base pH 9.0

Triton-X permeabilization step incubation period

Variations

Step

TABLE 2 Experimental conditions

10 mM sodium citrate, 0.05% Tween 20, 1 mM EDTA, pH 8.0
pH 6.0
Abcam recipe:
Abcam recipe:
0.37 g EDTA dissolved in 1 L of
2.94 g Tri-sodium citrate (dihydrate) deionized water. pH adjusted to 8.0
dissolved in 1 L of deionized water. pH with NaOH
adjusted to 6.0 with 1N HCl. 0.5 ml
Tween 20 added.

Sodium citrate pH 6.0

TABLE 1 List of buffers used

TABLE 1 Buffer Type and pH
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Sodium citrate pH 6.0

EDTA pH
168.0

Tris base pH 9.0

10 mM sodium citrate, 0.05% Tween 20, 1 mM EDTA, pH 8.0
pH 6.0
Abcam recipe:
Abcam recipe:
0.37 g EDTA dissolved in 1 L of
2.94 g Tri-sodium citrate (dihydrate) deionized water. pH adjusted to 8.0
dissolved in 1 L of deionized water. pH with NaOH
adjusted to 6.0 with 1N HCl. 0.5 ml
Tween 20 added.

10 mM Tris base, 1 mM EDTA solution,
0.05% Tween 20, pH 9.0
Abcam recipe:
1.21 g of Tris and 0.37 g of EDTA
dissolved in 1 L of deionized water. pH
adjusted to 9.0 with NaOH. 0.5 ml
Tween 20 added.

TABLE 22Experimental
conditions
TABLE
Experimental
conditions
Step

Variations

Bake slides

not performed
50-55 ℃ for 1 hour

Heat-induced antigen retrieval incubation period

0 minutes
20 minutes
30 minutes
1 hour

Heat-induced antigen retrieval water bath temperature

60 ℃
85-90 ℃

Triton-X permeabilization step incubation period

0 minutes
15 minutes
25 minutes

Blocking step duration with 50 mM ammonium chloride

0 minutes
15 minutes
30 minutes

Primary antibody incubation period

1 hour in room temperature; antibody diluted in
blocking buffer only
1 hour in room temperature; antibody diluted in
blocking buffer with Triton-X
Overnight incubation at 4 ℃; antibody diluted
in blocking buffer only

Secondary antibody incubation period

1 hour in room temperature
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TABLE 3 Primary antibodies used in Immunofluorescence assay

TABLE 3 Primary antibodies used in immunofluorescence assay
Antibody Target

Host/Isotype, clone

Source, catalog no.

Mouse monoclonal/IgG2aκ

LifeTechnologies, R960-25

GM130 (130kDa)

Mouse monoclonal/IgG1(κ), clone 35/GM130

BD Biosciences, 610822

EEA1 (180kDa)

Rabbit polyclonal

Abcam, ab2900

Mann II

Rabbit polyclonal

Abcam, ab12277

IE2 (86kDa)

Mouse monoclonal, clone 8B1.2

Chemicon (Millipore),
MAB810

pUL99 (pp28)

Mouse monoclonal/IgG2A(k), 5C3

Virusys, CA004-100

gB (55 kDa and 110 kDa)

Mouse monoclonal/ IgG1(k), clone 2F12

Virusys, CA005-100

Epitope tag
V5 (14 amino acids)
Cellular

HCMV
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DAPI

FITC

TexRed

Merge
FIG 4 Placenta Nuclei IE2 (Nucleus) GM130 (Golgi) EEA1

DAPI (Nucleus)
IE2 (Nucleus), GM130 (Golgi)
EEA1 (Early/recycling endosomes)

FIG 4 Placenta tissue infected with HCMV. IE2 staining is evident in the infected cells,
however, the Golgi and early endosomes are not detected in this slide. Infected cells may not
exhibit the typical kidney-bean shaped nucleus but are cytomegalic.
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A

B

DAPI (Nucleus)
IE2 (Nucleus)
gB (envelope protein, cytoplasmic)

DAPI (Nucleus)
IE2 (Nucleus)
pp28 (tegument protein, cytoplasmic)

FIG 5 Tissue slides that show positive viral nuclear and cytoplasmic staining. (A) Ovary
tissue. Arrows pointing at gB cytoplasmic staining of an infected cell. (B) Placenta tissue.
Arrow pointing at pp28 cytoplasmic staining of an infected cell.
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DAPI

FITC

TexRed

Merge

FIG 5 Colon Nuclei IE2 (Nucleus) GM130 (Golgi) EEA1

DAPI (Nucleus)
IE2 (Nucleus), GM130 (Golgi)
EEA1 (Early/recycling endosomes)

FIG 6 Colon tissue infected with HCMV. Orientation of the tissue section showed the
characteristic large kidney-bean shaped nucleus along with staining of the Golgi and early
endosomes in the cVAC area.
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FIG 7 Three dimensional aspects of an HCMV infected cell. Image from Das et al 2007.
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CHAPTER 3 ROLE OF pUL103 IN cVAC BIOGENESIS
Introduction
pUL103 is a tegument protein with known functions during the late replication cycle of
HCMV. Previous works in the Pellett laboratory have shown that pUL103 is involved in the
cVAC biogenesis, cell-to-cell spread, and virion maturation and egress (18). Contributors to the
assembly of the cVAC can be potential targets for new antivirals and warrant further study.
Here we try to address the question of whether the presence of pUL103 at early times
after infection is critical for cVAC biogenesis. To study the effects of pUL103, pUL103 was
fused with a destabilization domain (FKBP) that can be regulated by the presence or absence of
Shield-1 ligand. Shield-1 ligand attachment to the pUL103 construct stabilizes and protects it
from proteasomal degradation (Fig. 8) (19). The experimental design shown in Fig. 9 anticipates
that cVAC biogenesis occurs around 3 days post infection. pUL103 is a late protein and is
synthesized just prior to the cVAC, around 48 hours p.i., continuing throughout the course of the
infection. Previous siRNA knockdown experiments done in the Pellett lab have shown that less
pUL103 is synthesized late in the infection (18) represented in Fig. 9 (pUL103 siRNA) with a
thin bar compared to the wild type (pUL103 wt). With our pUL103-FKBP construct (pUL103FS+), if Shield-1 is present, input pUL103 from infecting virions and newly made pUL103
should be comparable to wild type levels. However in the absence of Shield-1, input pUL103 is
degraded more quickly, in addition, less are being synthesized. The experimental design aims to
determine whether the input pUL103 plays a role in the re-arranging of the cVAC area of an
infected cell and if reducing this amount will have an effect on that process.
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Materials and Methods
Human foreskin fibroblast (HFF) cells were seeded at 80% confluency on 0.2% gelatincoated 8-well glass chamber slides (Thermo Fisher Scientific, Waltham, MA). The next day, the
cells were infected with UL103-FKBP-V5 HCMV construct at 0.1 MOI and Shield-1 was added
in certain chamber wells under set time points of 0 hpi and then at 12 hour increments as
illustrated in Fig. 9. Shield-1 was replenished every 2 days in the corresponding wells. At 144
hpi, the slides were fixed with paraformaldehyde and stained and imaged as previously described
in Chapter 2. The number of infected cells with fully formed cVAC were quantified relative to
those without.
Results
Table 4 shows the results of the 2 experiments. In Experiment 1, 15% of infected cells
have well-formed cVAC in the absence of Shield-1 compared to 37% when Shield-1 was present
throughout the course of the experiment. When Shield-1 was omitted until later time points,
there was no defect in cVAC formation.
Experiment 2 differed from Experiment 1 in that it had more extended period prior to
addition of Shield-1. Experiment 2 has similar observations except that in the No Shield-1 added
control the fraction of cells with well-formed cVAC was higher than in Experiment 1 (30% vs.
15%), however, it was still lower than the other time points in the experiment.
Discussion
The objective of these experiments is to elucidate the role of input pUL103 in cVAC
biogenesis. Our results indicate that it is not critical for pUL103 to be present at wild type levels
during the early time of infection for cVAC biogenesis to occur.
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FIG 8 Regulatable Shield-1 ligand protects a protein of interest from proteasomal degradation.
Hagan EL, et al. 2009.
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CHAPTER 4 CONCLUSIONS
Human cytomegalovirus is a prevalent opportunistic pathogen that targets and cause
severe disease to those who have a weakened immune system. A hallmark characteristic of its
effect on the host cell is enlargement of nuclei and subsequent remodeling of the internal
structures to form the cytoplasmic virion assembly complex (cVAC) in the center. The cVAC is
the final site of virion maturation and egress, and viral proteins involved in its biogenesis are
potential targets for antivirals. To further learn about the pathogenesis of HCMV infection we
studied the structure of the cVAC in tissue slides from patients with congenital HCMV and
discovered that cVAC forms in tissue similar to cell cultures.

Previous work in the Pellett

laboratory had identified viral genes important in cVAC biogenesis, one of which is pUL103.
pUL103 is a multi-functional tegument protein that plays many other roles in the pathogenesis of
the infection.

To study its potential role during the early stages of cVAC biogenesis, we

conducted time point studies using a pUL103-FKBP construct whose presence in the infection
can be regulated with the addition of a Shield-1 ligand. Our findings suggest that input pUL103
at early stages of infection is not critical in the formation of cVAC at later times.
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Human Cytomegalovirus (HCMV) is a linear, double stranded DNA virus that causes
severe disease in the immunocompromised, and is one of the common cause of congenital
disease. Antivirals that are currently available for treatment target the DNA replication of the
virus cycle, and are highly toxic. Finding new drug targets, such as proteins responsible for
virion assembly and egress, would help to alleviate the disease burden.
HCMV remodels the host cell to form a structure called the cytoplasmic virion assembly
complex (cVAC), a site of virion maturation and egress. The first objective of this work is to
study the structure of the cVAC in vivo by immunofluorescence assay using slides from children
with congenital HCMV, and we discovered that the cVAC is also formed in vivo. The second
objective is to elucidate the role of pUL103 in cVAC biogenesis in the early stages of infection
using a regulatable pUL103-FKBP construct and Shield-1 ligand. We found that decreased
levels of pUL103 at the early stages of infection is not critical for cVAC biogenesis at later times
of the infection.
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